In a new survey, respondents said both vaccines were efficacious, but a higher share said influenza vaccines were very safe compared to COVID-19 vaccines. This demonstrates a public health concern considering the higher incidence rates and hospitalizations of COVID-19 over the flu, and the possibility of low vaccine intakes.
New and novel antimicrobials remain at a crossroads as the path to development and economic viability continue to be serious challenges. Our Editor-in-Chief weighs in on this topic and some of the other most significant ones from this past year.
Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.
In the fourth installment of RSV Roundtable, our panel explains the challenges in protecting the senior population against RSV.
This year saw the approval of new therapies as well as the continued evolution of time-to-treat infections and updated guidelines.
A study utilizing this technology identified specific predictive factors for developing hepatitis in diabetic patients.
In 2023, there were numerous developments in hepatitis C including the Biden Administration's new budget that put aside several billion dollars towards establishing a hepatitis C (HCV) program; the Cherokee Nation's Hepatitis C elimination program which has worked to increase screening and get people into the continuum of care; and how one clinician is bringing HCV care to the streets through her mobile clinics. Check out these stories and more from this year.
The current treatment pathway might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.
The first self-amplifying mRNA COVID-19 vaccine was approved in Japan; how email reminders fared in encouraging people with diabetes to get their influenza vaccines; in the latest RSV Roundtable, our panel discusses the addition of nirsevimab; and a biotech company is focused on the detection and diagnosis of viral diseases, with a particular interest in Long COVID.
In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.
United Kingdom-based Virax Biolabs is a biotech company that is focused on the detection and diagnosis of viral diseases, with a particular interest in the enigmatic, Long COVID.
Early treatment of the antiviral tecovirimat (TPOXX) could inhibit virus replication by more than 90%.
Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.
The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.
The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.
The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.
Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.
The 2 recalls were performed due to concerns about salmonella in the former and lead in the latter.
Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.
The ARCT-154 vaccine from CSL and Arcturus Therapeutics was approved in adults.
The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.
In the second installment of the RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.
In the news this week, the FDA approved the antifungal, isavuconazonium sulfate, which is indicated for children as young as 1 year of age; the continued clinical usefulness of doxycycline; examining infectious disease consults in gram-negative bacteremia; and a clinician utilizes mobile clinics to bring care to marginalized populations.
A study finds pathogen spores remain on surgical scrubs and patient gowns even after sodium hypochlorite disinfectant application. This finding presents an infection prevention challenge.
A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.
The implementation of clinical and specialty pharmacy services significantly increased the rate of patients transitioning from tenofovir disoproxil fumarate to tenofovir alafenamide.
Recent studies support the argument that all positive blood cultures trigger an automatic consultation.
A clinician utilizes mobile clinics to bring a hybrid of primary and urgent care to marginalized populations and help people overcome barriers and gets them into the continuum of care.
Investigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.
